echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Pan Shengzi applied for NASDAQ listing and lost more than 400 million yuan in the past two years

    Pan Shengzi applied for NASDAQ listing and lost more than 400 million yuan in the past two years

    • Last Update: 2019-11-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Yesterday, Mr Pan filed an initial public offering with the securities and Exchange Commission to raise up to $100 million In the 12 months to September 30, 2019, panshengzi achieved $42 million in sales and plans to go public on NASDAQ under the stock code GTH Credit Suisse and CICC, the joint bookrunners of the deal, did not disclose the pricing terms Pan Shengzi, headquartered in Beijing and founded in 2015, provides molecular analysis and diagnosis services for cancer patients, hundreds of scientific research institutions, hospitals and pharmaceutical enterprises through the business combination of "product + service" and "prevention and screening + personalized diagnosis and treatment + drug research and development services" From the public information of panspermia, it is found that in the field of personalized diagnosis and treatment, panspermia products and services involve a series of cancer species such as lung cancer, liver cancer, colorectal cancer, bladder cancer, breast cancer, gastric cancer, thyroid cancer and brain tumor; in the field of early screening of cancer, panspermia has developed technologies with high sensitivity and specificity, which have been verified in the line; in drug development services In the field of business, pan Shengzi has established strategic cooperation with a number of domestic and foreign pharmaceutical enterprises, and supported the clinical experiments and accompanying diagnosis of pharmaceutical enterprises According to the latest data of new cases of national malignant tumors, in 2015, there were 3.929 million new cases of national malignant tumors and 2.338 million deaths, accounting for 23.91% of the total causes of death of the residents In addition, in recent years, the incidence and death of malignant tumors have continued to rise, and the unmet clinical needs of patients in China are huge The opinions on the implementation of Health China action recently issued by the State Council focuses on the current major health problems and influencing factors, and puts cancer prevention and control on the agenda as a key point, clearly proposing that by 2022 and 2030, the overall 5-year survival rate of cancer will be no less than 43.3% and 46.6% respectively In the face of the huge tumor market, whether it is pharmaceutical companies, hospitals or gene testing companies, all are in a busy layout, with fierce competition According to the incomplete statistics of yiou health, there are 101 gene testing companies in China alone, including those established earlier and relatively "old" companies, such as BGI, Dean diagnostics, etc., as well as those established relatively later and taking tumor as one of their main businesses, such as berry gene, panspermia, Nuohe Zhiyuan, etc However, due to the limitations of precision medicine industry technology, China's cancer precision medicine is still in a long period of technology research and development, and the new treatment methods can not be applied on a large scale temporarily Among them, the high cost of R & D hinders many enterprises to make great progress According to the prospectus, pan child income mainly comes from diagnosis and monitoring services and products, and is highly dependent on these products for success As of December 31, 2017 and 2018, contract revenue from customers was 101 million yuan and 225 million yuan respectively, resulting in net losses of 421 million yuan and 465 million yuan respectively.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.